Listen to this articleDenmark-based Ascendis Pharma has nearly doubled its New Jersey footprint with the opening of an expanded Princeton office.
The global biopharmaceutical company, which focuses on treatments for rare endocrinology diseases, celebrated the milestone with an Oct. 16 ribbon cutting.
Located at 212 Carnegie Center Blvd., the 22,040-square-foot space can accommodate “well more than 100 employees,” the company noted. The firm previously housed nearly 50 employees in its 11,805-square-foot space and aims to grow.
Ascendis also noted its U.S workforce has more than doubled since 2024. In addition to its Princeton location, the company has another stateside office in Palo Alto, Calif., according to the company website.
At the event, Pamela Gavin, CEO of the National Organization for Rare Disorders (NORD), presented Jay Donovan Wu, executive vice president, US Market Ascendis Pharma, with a NORD Rare Impact Award for Industry Innovation. The honor recognized the company’s work developing and launching Yorvipath, the first treatment approved by the U.S. Food and Drug Administration for hypoparathyroidism in adults, according to Ascendis.
In February, BioNJ also recognized Ascendis with its annual Innovator Award for Yorvipath.
‘Doing the hard work’
In a LinkedIn post, NORD congratulated Ascendis, noting, “Innovation in #RareDisease isn’t easy — it demands persistence, vision, and unwavering commitment. Ascendis Pharma is doing the hard work: tackling complex science, investing in underserved communities, and delivering breakthroughs where they’re needed most.”
According to Ascendis, also on hand for the ribbon-cutting ceremony were:
- Assemblyman Roy Freiman, D-16th District
- Devin Mulroy, Freiman’s chief of staff
- Rachel Cohen, senior business development officer, Choose New Jersey
- Debbie Hart, president and CEO, BioNJ
- John Coelho, senior advisor, life sciences, New Jersey Economic Development Authority
Coelho also noted Ascendis’ accomplishments on LinkedIn, stating, “It is heartening to celebrate pioneering biotechnology companies emerge from the biotech winter, secure first-in-world FDA approvals and rapid patient access.
“Ascendis Pharma joins a growing list of [entrepreneurial] companies from rare disease to oncology, immunology and neurology which continue to defy the odds and have chosen to settle and expand in New Jersey,” Coelho continued.
